18704-37-5

Basic information

• Product Name: 8-Quinolinesulfonyl chloride
• Synonyms: Quinoline-8-sulfonylchloride,97%;8-Quinolinesulfonyl chloride >=96.0% (AT);8-Quinolinesulfonyl chloride 98%;8-Quinolinesulfonyl chloride≥ 98%(Titration);8-QUINOLINESULPHONYL CHLORIDE;AKOS B019400;ART-CHEM-BB B019400;QUINOLINE-8-SULPHONYL CHLORIDE
• CAS NO: 18704-37-5
• Molecular Formula: C₉H₆ClNO₂S
• Molecular Weight: 227.67
• EINECS: 242-515-5
• Product Categories: Chemical Synthesis;Heterocyclic Building Blocks;Quinoline&Isoquinoline;Heterocyclic Compounds;Condensation & Active Esterification;Quinolinecarboxylic Acids, etc.;Quinolines;Synthetic Organic Chemistry;Building Blocks;Heterocyclic Building Blocks;Building Blocks;C8 to C10
• Mol File: 18704-37-5.mol
• Article Data: 16

Chemical Properties

• Melting Point: 126-129 °C(lit.)
• Boiling Point: 306°C
• Flash Point: 306°C
• Appearance: white to light yellow crystal powder
• Density: 1.483 g/cm³
• Vapor Pressure: 0.012mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: 2-8°C
• Solubility: methanol: soluble10mg/mL, clear, colorless to light yellow
• PKA: 0?+-.0.17(Predicted)
• Sensitive: Moisture Sensitive
• BRN: 156347
• CAS DataBase Reference: 8-Quinolinesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Quinolinesulfonyl chloride(18704-37-5)
• EPA Substance Registry System: 8-Quinolinesulfonyl chloride(18704-37-5)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45-27
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• RTECS: VC2830000
• F: 3-10-21
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 18704-37-5(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powder

Uses

8-Quinolinesulfonyl chloride was used as a coupling reagent in oligonucleotide synthesis. It was also used in the synthesis of olefins from secondary esters at moderate temperature

General Description

8-Quinolinesulfonyl chloride reacts with aromatic/heterocyclic sulfonamides containing a free amino, imino, hydrazino or hydroxyl group to form water-soluble compounds.

InChI:InChI=1/C7H11BrN2/c1-7(2,3)6-5(8)4-9-10-6/h4H,1-3H3,(H,9,10)

Upstream product

• 91-22-5 quinoline 
• 491-33-8 8-mercaptoquinoline 
• 1160-28-7 bis(8-quinolinyl)disulfide 
• 16567-18-3 8-bromoquinoline 
• 35203-91-9 8-quinolinesulfonamide 
• 142597-99-7 1-(quinoline-8-sulphonyl)-3-n-butylurea 
• 85-48-3 8-quinolinesulfonic acid 

Downstream Products

• 35203-91-9 8-quinolinesulfonamide 
• 55180-87-5 8-quinolinesulfonyl azide 
• 1160-28-7 bis(8-quinolinyl)disulfide 
• 215511-35-6 Quinoline-8-sulfonic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide 
• 215511-68-5 Quinoline-8-sulfonic acid [5-(3-nitro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide 
• 197959-98-1 5-methyl-3-(quinolinyl-8-sulfonyloxy)phenol 
• 269746-61-4 (S)-2-[(2-Chloro-benzyl)-(quinoline-8-sulfonyl)-amino]-propionic acid 

Relevant articles and documents

-

-

Synthesis, Characterization, and Theoretical Studies of cis -Dichloridobis(8-quinolinethiolato)tin(iv) and bis(8-Sulfanylquinolinium) Hexachloridostannate(iv) Derivatives

The structural characterisation of bis(8-sulfanylquinolinium) hexachloridostannate(iv) (2) is reported and the variable reaction behaviour of this compound in different solvents has been explored. In particular, attempted recrystallization of 2 from chloroform and dichloromethane affords two polymorphs of cis-dichloridobis(8-quinolinethiolato)tin(iv), 3m and 3t, respectively. Attempted recrystallization of 2 from methanol gives crystals of 8,8′-dithiodiquinolinium hexachloridostannate(iv) 4. When 2 is dissolved in dimethyl sulfoxide in the presence of air, it undergoes oxidation to afford diquinolinyl-8,8′-disulfide 5. The molecular structures of the isolated compounds 2-4 are unambiguously authenticated by single crystal X-ray diffraction studies. The electronic structure properties of all the isolated compounds 2-4 are thoroughly studied by DFT calculations.

SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF AUTOIMMUNE, INFLAMMATION OR INFECTION RELATED DISORDERS

The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not limited to, the prophylaxis and/or treatment of autoimmune, inflammation, or infection related disorders.